Biogen (BIIB) Q4 FY25 earnings call: guidance and Q&A

How to think about the cadence of LEQEMBI sales growth, considering maintenance and the IQLIK, and its impact on revenue?

Chris Viehbacher indicated a 70% persistency for LEQEMBI maintenance, with most patients on monthly infusion. The subcutaneous pen is seeing progressive uptake despite lack of full reimbursement. He expects continued sequential linear growth, with potential acceleration in H2 2026 or 2027, especially if the IQLIK for induction is approved and fully reimbursed by payers in 2027. Increased use of blood-based diagnostics is also aiding patient identification.

“I think you're going to continue to see, as I said, that linear growth pattern. But I think we're also seeing some very strong response to direct-to-consumer advertising.”

asked by Alexandria Hammond · answered by Christopher Viehbacher

When does Biogen expect to return to overall revenue growth, and what role will growth products and business development play?

Chris Viehbacher noted that growth products outstripped MS decline last year, but 2026 will see more MS erosion (TECFIDERA, TYSABRI biosimilar). Return to growth requires positive Phase III results and product launches (e.g., litifilimab, felzartamab potentially launching in 2028). Business development is actively pursued for post-Phase III or early commercial assets, but finding value-generating opportunities at reasonable prices is challenging.

“I think to really return to growth, I think there's 2 things really need to happen. One is we do need to start seeing the positive Phase III results come out and the launch of products.”

asked by Philip Nadeau · answered by Christopher Viehbacher

How should the commercial opportunity for BIIB080 be considered compared to LEQEMBI, and what clinical data is needed for its success?

Chris Viehbacher emphasized that the neurology community views tau as a critical target, and BIIB080 can reduce tau. The key is whether tau reduction translates to cognitive improvement and its side effect profile (hoping for no ARIA-like events). He noted Alzheimer's is complex, likely requiring multiple modalities. If positive, it would be exciting but would still require a multi-year Phase III program.

“Every Alzheimer's expert I talk to really thinks tau is an important target. And if you look at the severity of Alzheimer's, that's really related to the level of tau.”

asked by Brian Skorney · answered by Christopher Viehbacher

Given mixed Phase II data and inherent risks in lupus, what drives Biogen's high conviction for litifilimab's Phase III outcome?

Priya Singhal stated high conviction stems from litifilimab's target (BDCA2 pathway on pDC cells, regulating type 1 interferon). Proof-of-concept data from the LILAC study (published in NEJM) for both systemic and cutaneous lupus supports this. The Phase III trials are designed to confirm these findings with an established primary endpoint (SRI-4) and targeted inclusion criteria relevant to the mechanism of action.

“we really believe that litifilimab is a high scientific conviction late-stage program. And the reason for this is that it targets the BDCA2 pathway, as you know.”

asked by Salveen Richter · answered by Priya Singhal

How important is the eGFR endpoint for felzartamab beyond the primary endpoint, and why limit development to kidney transplant AMR?

Priya Singhal confirmed eGFR is important, but the primary endpoint is the focus, with the totality of data mattering. The compelling magnitude of effect (>80%) in the small Phase II trial drives excitement. They are internally evaluating addressing CD38 autoantibodies in other organ transplants and initiating a sister trial for microvascular inflammation in kidney AMR. Chris Viehbacher added that some physicians are experimenting with CD38 in heart transplant, which they are monitoring.

“the magnitude of effect of greater than 80% that we saw in that small Phase II trial was really compelling.”

asked by Umer Raffat · answered by Priya Singhal

How will high-dose SPINRAZA approval in the U.S. affect rare disease top-line growth in 2026?

Chris Viehbacher noted strong initial results in Japan (first launch country), exceeding expectations with adoption and switchbacks. He highlighted increased efficacy with high dose, making the choice between oral convenience and SPINRAZA efficacy harder for physicians. Market research suggests sales increase, but actual sales will confirm. It's an important launch, highly anticipated by patient groups and physicians.

“Market research suggests that there could be an increase in sales, but I think I would say there's no market research like actual sales.”

asked by Evan Seigerman · answered by Christopher Viehbacher

How will Biogen pivot its commercial infrastructure for new launches, and what are the long-term commercial investment expectations and margin targets?

Chris Viehbacher emphasized acquiring experience and capability in new areas (transplant nephrologists, rheumatologists). He noted success in attracting talent from companies with strong presence in these areas. He doesn't foresee a massive impact on OpEx trajectory, as resources are reallocated from legacy businesses. Priya Singhal confirmed reallocation of resources. No long-term margin target was explicitly stated.

“I don't foresee that this is going to have a massive impact on our OpEx trajectory. But it is important that we have people who understand these spaces because as I always say, if you've launched one product, you've launched one product.”

asked by Brian Abrahams · answered by Christopher Viehbacher

Elaborate on priorities for the early-stage pipeline, specifically regarding high-risk, high-reward assets versus a balanced approach.

Chris Viehbacher clarified that Biogen isn't solely focused on high-risk, high-reward. ALS is less risky due to neurofilament biomarkers. Alzheimer's remains a core focus beyond tau. MS work is limited to progressive MS. The main expansion is into immunology, which is seen as cost-efficient due to portfolio opportunities within immune pathways. He expects more immunology than neuroscience in the early stage.

“No, I don't think we have the size as a company to be in the high-risk, high-reward business.”

asked by Christopher Schott · answered by Christopher Viehbacher